These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1124 related items for PubMed ID: 27460100

  • 1. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.
    Antimicrob Agents Chemother; 2017 Nov 26; 61(11):. PubMed ID: 28807915
    [Abstract] [Full Text] [Related]

  • 3. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L.
    Dig Dis Sci; 2017 Jun 26; 62(6):1580-1589. PubMed ID: 28391418
    [Abstract] [Full Text] [Related]

  • 4. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 5. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.
    Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ.
    Gut Microbes; 2020 Sep 02; 11(5):1314-1323. PubMed ID: 32362221
    [Abstract] [Full Text] [Related]

  • 6. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H.
    Am J Gastroenterol; 2016 Dec 02; 111(12):1736-1742. PubMed ID: 27670603
    [Abstract] [Full Text] [Related]

  • 7. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N, the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology.
    Antimicrob Agents Chemother; 2018 Sep 02; 62(9):. PubMed ID: 29914954
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P.
    PLoS One; 2018 Sep 02; 13(6):e0197096. PubMed ID: 29889843
    [Abstract] [Full Text] [Related]

  • 9. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar 02; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 10. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH.
    Helicobacter; 2020 Jun 02; 25(3):e12685. PubMed ID: 32141173
    [Abstract] [Full Text] [Related]

  • 11. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
    Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N.
    J Antimicrob Chemother; 2018 Jun 01; 73(6):1681-1687. PubMed ID: 29596646
    [Abstract] [Full Text] [Related]

  • 12. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X, Tan P, Song L, Lu Z.
    Am J Ther; 2016 Jun 01; 23(6):e1436-e1441. PubMed ID: 25923229
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
    Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I.
    Arab J Gastroenterol; 2017 Jun 01; 18(2):62-67. PubMed ID: 28601610
    [Abstract] [Full Text] [Related]

  • 14. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial.
    Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK.
    World J Gastroenterol; 2019 Dec 14; 25(46):6790-6798. PubMed ID: 31857780
    [Abstract] [Full Text] [Related]

  • 15. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS.
    World J Gastroenterol; 2015 Jan 07; 21(1):351-9. PubMed ID: 25574111
    [Abstract] [Full Text] [Related]

  • 16. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May 07; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 17. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M, Fayyad-Kazan M, Fayyad-Kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G.
    Microb Pathog; 2018 Apr 07; 117():23-26. PubMed ID: 29428426
    [Abstract] [Full Text] [Related]

  • 18. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
    Basyigit S, Kefeli A, Sapmaz F, Yeniova AO, Asilturk Z, Hokkaomeroglu M, Uzman M, Nazligul Y.
    Bosn J Basic Med Sci; 2015 Oct 25; 15(4):50-4. PubMed ID: 26614852
    [Abstract] [Full Text] [Related]

  • 19. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ.
    Korean J Gastroenterol; 2018 Apr 25; 71(4):196-203. PubMed ID: 29684968
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y.
    Med Princ Pract; 2017 Apr 25; 26(6):523-529. PubMed ID: 29131124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.